GlassScriptPhysician profile
Rachel Brady
NPI 1598298119
$2,212.71
in general payments reported to CMS, 2019-2025
24 companies · $216 in 2025
The $216 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $294 · 2021: $397 · 2022: $668 · 2023: $579 · 2024: $58.78 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $854.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $853.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $395.72 | 2021-2023 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $391.37 | 2020-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $341.63 | 2021-2024 | Mounjaro, Trulicity |
| Amgen INC. | $230.19 | 2023-2025 | Evenity, Repatha, Otezla |
| Glaxosmithkline, LLC. | $108.47 | 2020-2023 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $92.33 | 2020-2022 | |
| Lundbeck LLC | $82.32 | 2021-2023 | Rexulti |
| Axsome Therapeutics, INC. | $80.20 | 2022-2023 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $69.21 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.44 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $48.07 | 2021-2023 | |
| Exact Sciences Corporation | $44.61 | 2023 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $40.25 | 2020 | |
| Janssen Pharmaceuticals, INC | $39.89 | 2021-2022 | |
| Corium, LLC | $23.65 | 2023 | Azstarys |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $22.83 | 2021 | |
| Tris Pharma INC | $21.71 | 2023 | Dyanavel Xr |
| Mylan Specialty L.P. | $19.73 | 2021 | |
| Amarin Pharma, INC. | $19.68 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.71 | 2022 | |
| Merck Sharp & Dohme LLC | $17.25 | 2020 | |
| Pfizer INC. | $16.32 | 2022 | |
| Allergan, INC. | $13.72 | 2020 | |
| Gilead Sciences, INC. | $12.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Brady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.